Literature DB >> 11288945

Noninvasive diagnosis of deep vein thrombosis in postoperative patients.

C Kearon1.   

Abstract

The accuracy of noninvasive testing for the diagnosis of deep vein thrombosis (DVT) generally is less in asymptomatic patients than it is in those with symptoms suggestive of thrombosis. This is because asymptomatic DVT often is confined to the distal veins and, when it involves the proximal veins, the thrombi usually are smaller than in symptomatic patients with proximal thrombosis. Because the positive predictive value of noninvasive tests for asymptomatic DVT generally is 80% or less, abnormal results should be confirmed by venography. There are two main reasons why asymptomatic DVT is sought in the postoperative period: (1) to identify the need for full-dose anticoagulant therapy to prevent symptomatic episodes of venous thromboembolism (VTE), including fatal pulmonary embolism (this represents a form of secondary prophylaxis), and (2) to use this outcome as a surrogate for episodes of clinically important VTE in studies that are designed to evaluate methods of venous thrombosis prophylaxis. In relation to the first of these indications, evidence suggests that routine surveillance of high-risk patients to detect asymptomatic postoperative DVT does not result in improved clinical outcomes in patients who received appropriate VTE prophylaxis. In relation to the second indication, there is concern that asymptomatic VTE may not be a reliable surrogate for clinically important VTE, particularly if the effectiveness of different antithrombotic agents is being compared. Coupled with the comparatively low accuracy of noninvasive testing for asymptomatic DVT, this suggests that the results of such testing are unsuitable for the evaluation of new methods of prophylaxis in clinical trials.

Entities:  

Mesh:

Year:  2001        PMID: 11288945     DOI: 10.1055/s-2001-12842

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  6 in total

Review 1.  Missing something? A scoping review of venous thromboembolic events and their associations with bariatric surgery. Refining the evidence base.

Authors:  Walid El Ansari; Kareem El-Ansari
Journal:  Ann Med Surg (Lond)       Date:  2020-08-17

2.  High incidence of deep venous thrombosis after Achilles tendon rupture: a prospective study.

Authors:  Katarina Nilsson-Helander; Anders Thurin; Jon Karlsson; Bengt I Eriksson
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2009-02-24       Impact factor: 4.342

3.  A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.

Authors:  Laura McCullagh; Lesley Tilson; Cathal Walsh; Michael Barry
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

4.  Incidence of lower limbs deep vein thrombosis after open and laparoscopic gastric bypass: a prospective study.

Authors:  Aldo L Brasileiro; Fausto Miranda; João E M T M Ettinger; Aldemar A Castro; Guilherme B B Pitta; Liberato K de Moura; Euler Azaro; Marcelo L de Moura; Carlos A B Mello; Edvaldo Fahel; Luiz F P de Figueiredo
Journal:  Obes Surg       Date:  2007-12-15       Impact factor: 4.129

5.  Clinically important deep vein thrombosis in the intensive care unit: a survey of intensivists.

Authors:  Deborah Cook; Maureen Meade; Gordon Guyatt; Lauren Griffith; John Granton; William Geerts; Mark Crowther
Journal:  Crit Care       Date:  2004-05-06       Impact factor: 9.097

6.  Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study).

Authors:  Davide Imberti; Edoardo Baldini; Matteo Giorgi Pierfranceschi; Alberto Nicolini; Concetto Cartelli; Marco De Paoli; Marcello Boni; Esmeralda Filippucci; Stefano Cariani; Giorgio Bottani
Journal:  Obes Surg       Date:  2014-02       Impact factor: 4.129

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.